↓ Skip to main content

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

Overview of attention for article published in Cancer Immunology, Immunotherapy, April 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

twitter
10 tweeters
patent
4 patents

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
67 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers
Published in
Cancer Immunology, Immunotherapy, April 2012
DOI 10.1007/s00262-012-1259-8
Pubmed ID
Authors

Kelly Barrios, Esteban Celis

Abstract

Therapeutic vaccines for cancer are an attractive alternative to conventional therapies, since the later result in serious adverse effects and in most cases are not effective against advanced disease. Human papillomavirus (HPV) is responsible for several malignancies such as cervical carcinoma. Vaccines targeting oncogenic viral proteins like HPV16-E6 and HPV16-E7 are ideal candidates to elicit strong immune responses without generating autoimmunity because: (1) these products are not expressed in normal cells and (2) their expression is required to maintain the malignant phenotype. Our group has developed peptide vaccination strategy called TriVax, which is effective in generating vast numbers of antigen-specific T cells in mice capable of persisting for long time periods.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
Portugal 1 1%
South Africa 1 1%
Unknown 64 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 30%
Student > Ph. D. Student 11 16%
Student > Master 7 10%
Student > Doctoral Student 6 9%
Professor > Associate Professor 5 7%
Other 12 18%
Unknown 6 9%
Readers by discipline Count As %
Agricultural and Biological Sciences 17 25%
Medicine and Dentistry 12 18%
Immunology and Microbiology 12 18%
Biochemistry, Genetics and Molecular Biology 9 13%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Other 7 10%
Unknown 8 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 May 2020.
All research outputs
#1,731,197
of 17,814,645 outputs
Outputs from Cancer Immunology, Immunotherapy
#75
of 2,496 outputs
Outputs of similar age
#11,683
of 133,052 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#1
of 24 outputs
Altmetric has tracked 17,814,645 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,496 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 133,052 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.